Heart Disease: The #1 Killer of Women
Heart Health & Hormones
Heart Disease: The #1 Killer of Women
"But I thought I only needed to worry about breast cancer!?"
And because of a misinterpretation of data from the Women’s Health Initiative (WHI), we’ve been denying women the very treatment that reduces the risk of both heart disease and breast cancer. It’s one of the most consequential mistakes in women’s medicine — and it’s time to correct the record.
So what does menopause have to do with heart disease?
Estrogen has a profound protective effect on blood vessels and the cardiovascular system. Prior to the severe estrogen loss that occurs at menopause, women have lower rates of heart disease than men. Estrogen helps keep arterial walls flexible, reduces inflammation, and supports healthy cholesterol levels.
But once a woman has been without adequate estrogen for 10 years, her vascular risk begins to mirror that of her male contemporaries. The protection disappears — and the gap closes.
Key finding
Early initiation of menopausal hormone therapy (MHT) leads to a significant reduction in the incidence of later heart disease.
What can be done?
Early initiation of menopausal hormone therapy — formerly called HRT, now more precisely referred to as MHT — leads to a significant reduction in the incidence of later cardiovascular disease. This is sometimes called the “timing hypothesis” or the window of opportunity: the earlier treatment begins relative to menopause, the greater the cardiovascular benefit.
What does “early” mean here?
Perimenopause.
Yes — the 39-year-old who chooses MHT to treat her hot flashes, mood swings, poor sleep, and urinary symptoms is also choosing better heart health for her 70-year-old self. That’s not a side benefit. That’s the point. The decision you make at 39 or 45 or 51 ripples forward across decades.
The WHI — and why the data got so distorted
The 2002 WHI study caused a mass exodus from hormone therapy when headlines reported increased risks. What those headlines missed: the average participant was 63 years old — more than a decade past menopause. The findings simply do not apply to women in their 40s and early 50s who are newly perimenopausal or menopausal.
The medical community is still recovering from that overcorrection. Many women today are being undertreated — or not treated at all — based on fear rooted in misapplied science.
The bottom line
Heart disease kills more women than any other condition. The perimenopause years — often dismissed as a time of mere “symptoms” — are actually a critical window for cardiovascular prevention. MHT, initiated at the right time and in the right patient, is one of the most powerful tools we have.
If you’re in perimenopause and wondering whether hormone therapy is right for you, this conversation deserves space, time, and a clinician who is up to date on the evidence. That’s exactly what we do at Magnolia Midlife.
Book a free meet-and-greet at Magnolia Midlife Women’s Health.
